Back to Browse Journals » OncoTargets and Therapy » Volume 3

First-line treatment of chronic lymphocytic leukemia: role of alemtuzumab

Authors Carmen Diana Schweighofer, Clemens-Martin Wendtner

Published Date March 2010 Volume 2010:3 Pages 53—67

DOI http://dx.doi.org/10.2147/OTT.S3099

Published 30 March 2010

Carmen Diana Schweighofer1, Clemens-Martin Wendtner2

1Department of Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA; 2Department of Internal Medicine I, University of Cologne, Cologne, Germany

Abstract: The CD52-targeting antibody alemtuzumab is established in clinical practice with convincing activity in relapsed and refractory chronic lymphocytic leukemia (CLL), particularly in patients with high-risk features and adverse prognosis. In the CAM307 study alemtuzumab was tested and finally approved as a first-line single agent, even though the hurdle with chlorambucil as the contender was not set very high. Within clinical trials, the drug demonstrated an excellent ability to eliminate minimal residual disease in blood and bone marrow, which has been correlated with a corresponding survival advantage in patients. However, in the maintenance setting, infectious complications due to severe T cell suppression have been highlighted and do not allow clinicans to use alemtuzumab outside of clinical trials. This review discusses potential therapeutic niches and future applications of alemtuzumab with a focus on CLL front-line treatment.
Keywords: CLL, alemtuzumab, Campath, front-line, first-line treatment

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Association of retinal vessel attenuation with visual function in eyes with retinitis pigmentosa

Nakagawa S, Oishi A, Ogino K, Makiyama Y, Kurimoto M, Yoshimura N

Clinical Ophthalmology 2014, 8:1487-1493

Published Date: 12 August 2014

Physicochemical features and transfection properties of chitosan/poloxamer 188/poly(D,L-lactide-co-glycolide) nanoplexes

Cosco D, Federico C, Maiuolo J, Bulotta S, Molinaro R, Paolino D, Tassone P, Fresta M

International Journal of Nanomedicine 2014, 9:2359-2372

Published Date: 15 May 2014

Sequential release of salidroside and paeonol from a nanosphere-hydrogel system inhibits ultraviolet B-induced melanogenesis in guinea pig skin

Peng LH, Xu SY, Shan YH, Wei W, Liu S, Zhang CZ, Wu JH, Liang WQ, Gao JQ

International Journal of Nanomedicine 2014, 9:1897-1908

Published Date: 16 April 2014

Effect of ranibizumab on serous and vascular pigment epithelial detachments associated with exudative age-related macular degeneration

Panos GD, Gatzioufas Z, Petropoulos IK, Dardabounis D, Thumann G, Hafezi F

Drug Design, Development and Therapy 2013, 7:565-569

Published Date: 10 July 2013

Applicability of the Rivermead Behavioural Memory Test – Third Edition (RBMT-3) in Korsakoff's syndrome and chronic alcoholics

Wester AJ, van Herten JC, Egger JI, Kessels RP

Neuropsychiatric Disease and Treatment 2013, 9:875-881

Published Date: 21 June 2013

Ex vivo laser confocal microscopy findings of cultured Acanthamoeba trophozoites

Yamazaki N, Kobayashi A, Yokogawa H, Ishibashi Y, Oikawa Y, Tokoro M, Sugiyama K

Clinical Ophthalmology 2012, 6:1365-1368

Published Date: 22 August 2012

Clinical utility of ultrasound guidance for intra-articular knee injections: a review

Berkoff DJ, Miller LE, Block JE

Clinical Interventions in Aging 2012, 7:89-95

Published Date: 20 March 2012